Skip to main content

Advertisement

Fig. 3 | Respiratory Research

Fig. 3

From: Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Fig. 3

Decline in FVC in subjects with baseline FVC > 90% and ≤ 90% predicted in the INPULSIS trials of nintedanib [13]. Error bars show the standard error. FVC, forced vital capacity. Republished with permission of Thorax, from Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume, Kolb et al., 72, 2017; permission conveyed through Copyright Clearance Center, Inc.

Back to article page